This report provides a comprehensive analysis of the global non-invasive cancer detection market, projecting significant growth through 2032. It examines key technologies such as liquid biopsy, genetic testing, and imaging used to analyze biomarkers in body fluids for early diagnosis and disease monitoring. The study explores market dynamics across various cancer types and geographies, including the Americas, APAC, and Europe. Additionally, the report evaluates competitive landscapes, industry trends, and the strategic positioning of leading players like Trublood and Owlstone Medical.

Executive Overview

The global Non-Invasive Cancer Detection market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Non-invasive cancer testing is a technology that detects cancer by analyzing biomarkers in body fluids such as blood, urine, and saliva without surgery or tissue biopsy. Common non-invasive testing methods include liquid biopsy, genetic testing, and imaging technology, which can detect cancer-related DNA, RNA, proteins, or circulating tumor cells (CTCs) to detect cancer early or monitor disease progression. Non-invasive testing is more comfortable for patients and has lower risks, and is particularly suitable for cancer screening, treatment effect evaluation, and recurrence monitoring.

Regional Market Outlook

• United States: The market is estimated to increase significantly from 2025 through 2032, growing at a sustained compound annual growth rate.
• China: The market is estimated to increase significantly from 2025 through 2032, growing at a sustained compound annual growth rate.
• Europe: The market is estimated to increase significantly from 2025 through 2032, growing at a sustained compound annual growth rate.

Market Segmentation

By Type

• Imaging Test
• Nuclear Medicine Test
• Others

By Application

• Prostate Cancer
• Bladder Cancer
• Pancreatic Cancer
• Breast Cancer
• Gastric Cancer
• Others

By Geography

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

The global Non-Invasive Cancer Detection market features several key players, with the two largest companies occupying a significant portion of the total market share in 2025.

Key Players

The following companies have been profiled based on inputs gathered from primary experts and analyses of company coverage, product portfolios, and market penetration:

• Trublood
• Datar Cancer Genetics
• Nucleix
• miR Scientific
• Owlstone Medical
• bioAffinity Technologies
• Nonacus
• Amadix

Report Scope and Methodology

LPI (LP Information)' newest research report, the “Non-Invasive Cancer Detection Industry Forecast” looks at past sales and reviews total world Non-Invasive Cancer Detection sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-Invasive Cancer Detection sales for 2026 through 2032. With Non-Invasive Cancer Detection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Invasive Cancer Detection industry.

This Insight Report provides a comprehensive analysis of the global Non-Invasive Cancer Detection landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyses the strategies of leading global companies with a focus on Non-Invasive Cancer Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Invasive Cancer Detection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Invasive Cancer Detection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Invasive Cancer Detection. The report presents a comprehensive overview, market shares, and growth opportunities of the Non-Invasive Cancer Detection market by product type, application, key players, and key regions and countries.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Non-Invasive Cancer Detection Market Size (2021-2032)

    • 2.1.2 Non-Invasive Cancer Detection Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Non-Invasive Cancer Detection by Country/Region (2021, 2025 & 2032)

  • 2.2 Non-Invasive Cancer Detection Segment by Type

    • 2.2.1 Imaging Test

    • 2.2.2 Nuclear Medicine Test

    • 2.2.3 Others

    • 2.2.4 Non-Invasive Cancer Detection Market Size by Type

      • 2.2.4.1 Non-Invasive Cancer Detection Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global Non-Invasive Cancer Detection Market Size Market Share by Type (2021-2026)

  • 2.3 Non-Invasive Cancer Detection Segment by Application

    • 2.3.1 Prostate Cancer

    • 2.3.2 Bladder Cancer

    • 2.3.3 Pancreatic Cancer

    • 2.3.4 Breast Cancer

    • 2.3.5 Gastric Cancer

    • 2.3.6 Others

    • 2.3.7 Non-Invasive Cancer Detection Market Size by Application

      • 2.3.7.1 Non-Invasive Cancer Detection Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.7.2 Global Non-Invasive Cancer Detection Market Size Market Share by Application (2021-2026)

• 3 Non-Invasive Cancer Detection Market Size by Player

  • 3.1 Non-Invasive Cancer Detection Market Size Market Share by Player

    • 3.1.1 Global Non-Invasive Cancer Detection Revenue by Player (2021-2026)

    • 3.1.2 Global Non-Invasive Cancer Detection Revenue Market Share by Player (2021-2026)

  • 3.2 Global Non-Invasive Cancer Detection Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Non-Invasive Cancer Detection by Region

  • 4.1 Non-Invasive Cancer Detection Market Size by Region (2021-2026)

  • 4.2 Global Non-Invasive Cancer Detection Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Non-Invasive Cancer Detection Market Size Growth (2021-2026)

  • 4.4 APAC Non-Invasive Cancer Detection Market Size Growth (2021-2026)

  • 4.5 Europe Non-Invasive Cancer Detection Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Non-Invasive Cancer Detection Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Non-Invasive Cancer Detection Market Size by Country (2021-2026)

  • 5.2 Americas Non-Invasive Cancer Detection Market Size by Type (2021-2026)

  • 5.3 Americas Non-Invasive Cancer Detection Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Non-Invasive Cancer Detection Market Size by Region (2021-2026)

  • 6.2 APAC Non-Invasive Cancer Detection Market Size by Type (2021-2026)

  • 6.3 APAC Non-Invasive Cancer Detection Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Non-Invasive Cancer Detection Market Size by Country (2021-2026)

  • 7.2 Europe Non-Invasive Cancer Detection Market Size by Type (2021-2026)

  • 7.3 Europe Non-Invasive Cancer Detection Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Non-Invasive Cancer Detection by Region (2021-2026)

  • 8.2 Middle East & Africa Non-Invasive Cancer Detection Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Non-Invasive Cancer Detection Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Non-Invasive Cancer Detection Market Forecast

  • 10.1 Global Non-Invasive Cancer Detection Forecast by Region (2027-2032)

    • 10.1.1 Global Non-Invasive Cancer Detection Forecast by Region (2027-2032)

    • 10.1.2 Americas Non-Invasive Cancer Detection Forecast

    • 10.1.3 APAC Non-Invasive Cancer Detection Forecast

    • 10.1.4 Europe Non-Invasive Cancer Detection Forecast

    • 10.1.5 Middle East & Africa Non-Invasive Cancer Detection Forecast

  • 10.2 Americas Non-Invasive Cancer Detection Forecast by Country (2027-2032)

    • 10.2.1 United States Market Non-Invasive Cancer Detection Forecast

    • 10.2.2 Canada Market Non-Invasive Cancer Detection Forecast

    • 10.2.3 Mexico Market Non-Invasive Cancer Detection Forecast

    • 10.2.4 Brazil Market Non-Invasive Cancer Detection Forecast

  • 10.3 APAC Non-Invasive Cancer Detection Forecast by Region (2027-2032)

    • 10.3.1 China Non-Invasive Cancer Detection Market Forecast

    • 10.3.2 Japan Market Non-Invasive Cancer Detection Forecast

    • 10.3.3 Korea Market Non-Invasive Cancer Detection Forecast

    • 10.3.4 Southeast Asia Market Non-Invasive Cancer Detection Forecast

    • 10.3.5 India Market Non-Invasive Cancer Detection Forecast

    • 10.3.6 Australia Market Non-Invasive Cancer Detection Forecast

  • 10.4 Europe Non-Invasive Cancer Detection Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Non-Invasive Cancer Detection Forecast

    • 10.4.2 France Market Non-Invasive Cancer Detection Forecast

    • 10.4.3 UK Market Non-Invasive Cancer Detection Forecast

    • 10.4.4 Italy Market Non-Invasive Cancer Detection Forecast

    • 10.4.5 Russia Market Non-Invasive Cancer Detection Forecast

  • 10.5 Middle East & Africa Non-Invasive Cancer Detection Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Non-Invasive Cancer Detection Forecast

    • 10.5.2 South Africa Market Non-Invasive Cancer Detection Forecast

    • 10.5.3 Israel Market Non-Invasive Cancer Detection Forecast

    • 10.5.4 Turkey Market Non-Invasive Cancer Detection Forecast

  • 10.6 Global Non-Invasive Cancer Detection Forecast by Type (2027-2032)

  • 10.7 Global Non-Invasive Cancer Detection Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Non-Invasive Cancer Detection Forecast

• 11 Key Players Analysis

  • 11.1 Trublood

    • 11.1.1 Trublood Company Information

    • 11.1.2 Trublood Non-Invasive Cancer Detection Product Offered

    • 11.1.3 Trublood Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Trublood Main Business Overview

    • 11.1.5 Trublood Latest Developments

  • 11.2 Datar Cancer Genetics

    • 11.2.1 Datar Cancer Genetics Company Information

    • 11.2.2 Datar Cancer Genetics Non-Invasive Cancer Detection Product Offered

    • 11.2.3 Datar Cancer Genetics Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Datar Cancer Genetics Main Business Overview

    • 11.2.5 Datar Cancer Genetics Latest Developments

  • 11.3 Nucleix

    • 11.3.1 Nucleix Company Information

    • 11.3.2 Nucleix Non-Invasive Cancer Detection Product Offered

    • 11.3.3 Nucleix Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Nucleix Main Business Overview

    • 11.3.5 Nucleix Latest Developments

  • 11.4 miR Scientific

    • 11.4.1 miR Scientific Company Information

    • 11.4.2 miR Scientific Non-Invasive Cancer Detection Product Offered

    • 11.4.3 miR Scientific Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 miR Scientific Main Business Overview

    • 11.4.5 miR Scientific Latest Developments

  • 11.5 Owlstone Medical

    • 11.5.1 Owlstone Medical Company Information

    • 11.5.2 Owlstone Medical Non-Invasive Cancer Detection Product Offered

    • 11.5.3 Owlstone Medical Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Owlstone Medical Main Business Overview

    • 11.5.5 Owlstone Medical Latest Developments

  • 11.6 bioAffinity Technologies

    • 11.6.1 bioAffinity Technologies Company Information

    • 11.6.2 bioAffinity Technologies Non-Invasive Cancer Detection Product Offered

    • 11.6.3 bioAffinity Technologies Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 bioAffinity Technologies Main Business Overview

    • 11.6.5 bioAffinity Technologies Latest Developments

  • 11.7 Nonacus

    • 11.7.1 Nonacus Company Information

    • 11.7.2 Nonacus Non-Invasive Cancer Detection Product Offered

    • 11.7.3 Nonacus Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Nonacus Main Business Overview

    • 11.7.5 Nonacus Latest Developments

  • 11.8 Amadix

    • 11.8.1 Amadix Company Information

    • 11.8.2 Amadix Non-Invasive Cancer Detection Product Offered

    • 11.8.3 Amadix Non-Invasive Cancer Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Amadix Main Business Overview

    • 11.8.5 Amadix Latest Developments

• 12 Research Findings and Conclusion